Taltz® (ixekizumab) Auto-Injector and Prefilled Syringe

What Taltz® Is and How It Works

Taltz® (ixekizumab) is a prescription biologic for immune‑mediated conditions. It treats moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis (radiographic axial spondyloarthritis), and non‑radiographic axial spondyloarthritis. This page explains indications, dosing, device options, and taltz price so you can plan your therapy and ordering.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We partner with vetted, licensed pharmacies to supply authentic brand medications with a broad selection and value‑focused pricing.

Ixekizumab is a monoclonal antibody that targets interleukin‑17A (IL‑17A). By blocking IL‑17A, it reduces inflammation in skin, joints, and the axial skeleton. Taltz is given as a subcutaneous injection using either a prefilled autoinjector or a prefilled syringe. Many adults start with a loading dose, then continue with maintenance injections every four weeks. For plaque psoriasis, dosing begins more frequently and then spaces out as maintenance starts.

Not all patients need the same schedule. Your clinician will tailor the dose based on the condition treated, response, and tolerability.

Dosage and Usage

• Starting dose for adults (many indications): 160 mg at week 0 (two 80 mg injections).
• Plaque psoriasis: after the 160 mg loading dose, inject 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
• Psoriatic arthritis: 160 mg loading dose, then 80 mg every 4 weeks. If coexisting moderate to severe plaque psoriasis, your clinician may follow the plaque psoriasis schedule.
• Ankylosing spondylitis and non‑radiographic axial spondyloarthritis: 160 mg loading dose, then 80 mg every 4 weeks.
• Subcutaneous injection sites: abdomen (avoid the 2‑inch area around the navel), front of thighs, or back of the upper arm if given by a caregiver.
• Autoinjector/prefilled syringe steps (general): remove from the refrigerator and allow to reach room temperature (about 30 minutes). Do not shake. Inspect the solution; it should be clear to slightly yellow and free of large particles. Clean the skin with an alcohol swab. Inject at a 90‑degree angle with the autoinjector, or as instructed for the prefilled syringe. Confirm completion via the device indicator, apply gentle pressure with gauze, and dispose of the device in a sharps container.
• Missed dose: administer as soon as you remember, then resume your established schedule. Do not take two doses at the same time.

• Storage: keep refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light in the original carton. Do not shake.
• Room temperature allowance: may be kept at room temperature up to 30°C (86°F) for a total of 5 days. Once stored at room temperature, do not return to the refrigerator. If not used within 5 days, discard.
• Travel tips: use an insulated bag with gel packs; do not place the pen or syringe directly on ice. Keep in the original carton with labels visible. Allow to warm to room temperature before injecting. Carry a backup dose if advised and a sharps container or travel‑safe alternative.
• Handling: do not use if dropped on a hard surface, damaged, or the solution looks cloudy, discolored, or contains large particles.

Benefits and Savings

Taltz reduces psoriasis plaques and itch, often starting within the first few weeks. Many people achieve clear or almost clear skin by 12 weeks and maintain control with monthly maintenance. In psoriatic arthritis, it improves tender and swollen joints, skin lesions, and function. In axial spondyloarthritis, it reduces back pain, stiffness, and MRI signs of inflammation.

The autoinjector and prefilled syringe offer flexibility for self‑injection at home. A monthly maintenance schedule after initial dosing supports long‑term disease control. Many customers save 60–80% vs typical U.S. prices when ordering through CanadianInsulin, with prompt, express, cold‑chain shipping.

See our promotions page for current offers, including any taltz coupon if available.

Side Effects and Safety

• Common: injection site redness or pain, upper respiratory infections, nausea.
• Infections: fungal infections (including oral or genital candidiasis), tinea, and conjunctivitis may occur.
• Other reported: headache, fatigue, diarrhea, and mild neutropenia.

Serious risks include severe infections. Your clinician may test for tuberculosis before starting and during therapy. Do not receive live vaccines while using ixekizumab. Hypersensitivity reactions can occur; get urgent care for signs of anaphylaxis. New onset or worsening inflammatory bowel disease has been reported; tell your clinician about any persistent abdominal pain or blood in stool. Discuss pregnancy and breastfeeding plans with your prescriber.

Onset Time

Skin improvement can begin in 1 to 2 weeks, with larger gains through weeks 8 to 12 as the dose schedule stabilizes. Many patients reach significant plaque clearance by week 12 and sustain response on every‑4‑week maintenance.

Joint symptom relief in psoriatic arthritis may start within 2 to 4 weeks, with continued improvement over 3 to 4 months. In ankylosing spondylitis and non‑radiographic axial spondyloarthritis, back pain and stiffness often improve between 4 and 12 weeks. Individual response varies.

Compare With Alternatives

Cosentyx® (secukinumab) is another IL‑17A inhibitor used for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. It offers monthly maintenance dosing after an initial period. If you prefer this brand, you can review Cosentyx for details and device options.

Enbrel® (etanercept) is a TNF inhibitor approved for psoriasis and psoriatic arthritis. It is dosed weekly for many patients and has a long track record. Compare features and device formats on our Enbrel Pre Filled Syringe page to see which approach fits your treatment plan.

Your prescriber will help choose among classes based on your diagnosis, prior therapies, comorbidities, and vaccination status.

Combination Therapy

• Psoriatic arthritis: may be used alone or with methotrexate. Your clinician may adjust background DMARDs based on response and tolerability.
• Plaque psoriasis: can be combined with topical corticosteroids or vitamin D analogs for localized plaques.
• Axial spondyloarthritis: may be used with NSAIDs for symptom control, per clinician guidance.
• Avoid combining with other biologic immunomodulators unless your specialist directs otherwise.

Patient Suitability and Cost‑Saving Tips

Adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy may be considered for ixekizumab. It is also used for active psoriatic arthritis, ankylosing spondylitis, and non‑radiographic axial spondyloarthritis with objective signs of inflammation. Pediatric use for plaque psoriasis is weight‑based; your clinician will determine eligibility.

It may not be suitable if you have an active infection, untreated latent tuberculosis, or a history of inflammatory bowel disease flares with IL‑17 inhibitors. Discuss vaccination plans before starting; avoid live vaccines during treatment. Review your medical history, pregnancy plans, and current medicines with your prescriber.

Cost‑saving ideas include choosing multi‑month supplies when appropriate, comparing autoinjector versus prefilled syringe device options, and setting reorder reminders so you do not pay for last‑minute local replacements. CanadianInsulin uses prompt, express, cold‑chain shipping to protect temperature‑sensitive products.

Authoritative Sources

Eli Lilly: Taltz product information and support

Health Canada Drug Product Database: Ixekizumab (Taltz) entry

FDA Prescribing Information: Taltz (ixekizumab) injection

Order Taltz® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace advice from your own healthcare professional. Always follow your prescriber’s instructions and the product labeling.